Abstract
Despite many technical advances (intraoperative resection control, fluorescence guided resection, advances in external beam radiation techniques) and new consolidated findings on systemic chemotherapy, treatment of malignant gliomas with conventional modalities (surgery, radiation therapy, and chemotherapy) is still highly unfavorable. Total tumor eradication is impossible due to tumor infiltrations into the surrounding normal brain tissue and the limitations given by its limited tolerance. New treatment strategies, therefore, aim for a more selective destruction of tumor cells. Malignant gliomas express several antigens or receptors which are not or only to a minor extent present in normal brain tissue. Administration of radiolabeled monoclonal antibodies targeting these tumor-specific structures, especially when given locoregionally, offers an innovative therapeutic strategy that has demonstrated encouraging antitumor effects and acceptable toxicity in many phase I/II clinical trials. This chapter offers a comprehensive summary of own experiences and results of clinical trials reported in the literature dealing with radioimmunotherapy of malignant glioma and highlights future plans to further develop this therapeutic strategy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bartolomei M, Mazzetta C, Handkiewicz-Junak D et al (2004) Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging 48:220–228
Bigner DD, Brown MT, Friedman AH et al (1998) Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16:2202–2212
Boiardi A, Bartolomei M, Silvani A et al (2005) Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol 72:125–131
Brack SS, Silacci M, Birchler M et al (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12:3200–3208
Brady LW, Markoe AM, Woo DV et al (1990a) Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme: a pilot study. Front Radiat Ther Oncol 24:151–160 (discussion 161–165)
Brady LW, Markoe AM, Woo DV et al (1990b) Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas: a pilot study. J Neurosurg Sci 34:243–249
Casaco A, Lopez G, Garcia I et al (2008) Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 7:333–339
Cokgor I, Akabani G, Kuan CT et al (2000) Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862–3872
De Santis R, Albertoni C, Petronzelli F et al (2006) Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res 12:2191–2196
Emrich JG, Brady LW, Quang TS et al (2002) Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol 25:541–546
Goetz C, Rachinger W, Poepperl G et al (2003) Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings. Acta Neurochir Suppl 88:69–75
Goetz CM, Rachinger W, Decker M et al (2005) Distribution of labeled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats. Cancer Immunol Immunother 54:337–344
Grana C, Chinol M, Robertson C et al (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–212
Hauck ML, Zalutsky MR (2005a) Enhanced tumour uptake of radiolabeled antibodies by hyperthermia. Part II: application of the thermal equivalency equation. Int J Hyperthermia 21:13–27
Hauck ML, Zalutsky MR (2005b) Enhanced tumour uptake of radiolabeled antibodies by hyperthermia: Part I: timing of injection relative to hyperthermia. Int J Hyperthermia 21:1–11
Herold-Mende C, Mueller MM, Bonsanto MM et al (2002) Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 98:362–369
Hopkins K, Papanastassiou V, Kemshead JT (1996) The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates. Recent Results Cancer Res 141:159–175
Kim CH, Bak KH, Kim YS et al (2000) Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surg Neurol 54:235–240
Kleihues P, Cavenee WK (2000) Tumors of the nervous system. Pathology and genetics. IARC press, Lyon, France
Leins A, Riva P, Lindstedt R et al (2003) Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98:2430–2439
Lund-Johansen M, Bjerkvig R, Humphrey PA et al (1990) Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50:6039–6044
Paganelli G, Grana C, Chinol M et al (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348–357
Paganelli G, Bartolomei M, Ferrari M et al (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227–235
Paganelli G, Bartolomei M, Grana C et al (2006) Radioimmunotherapy of brain tumor. Neurol Res 28:518–522
Patel SJ, Shapiro WR, Laske DW et al (2005) Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:1243–1252 discussion 1252–1253
Petronzelli F, Pelliccia A, Anastasi AM et al (2005) Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res 11:7137s–7145s
Quang TS, Brady LW (2004) Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58:972–975
Reardon DA, Akabani G, Coleman RE et al (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397
Reardon DA, Akabani G, Coleman RE et al (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24:115–122
Reardon DA, Zalutsky MR, Bigner DD (2007) Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther 7:675–687
Reardon DA, Zalutsky MR, Akabani G et al (2008) A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 10(2):182–189
Reist CJ, Bigner DD, Zalutsky MR (1998) Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res 4:2495–2502
Riva P, Arista A, Sturiale C et al (1992) Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labeled anti-tenascin monoclonal antibody BC-2. Int J Cancer 51:7–13
Riva P, Franceschi G, Frattarelli M et al (1999a) Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin Cancer Res 5:3275s–3280s
Riva P, Franceschi G, Frattarelli M et al (1999b) 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma–phase I and II study. Acta Oncol 38:351–359
Riva P, Franceschi G, Riva N et al (2000) Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 27:601–609
Sasaki H, Yoshida K, Ikeda E et al (1998) Expression of the neural cell adhesion molecule in astrocytic tumors: an inverse correlation with malignancy. Cancer 82:1921–1931
Schold SC Jr, Zalutsky MR, Coleman RE et al (1993) Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol 28:488–496
Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Todaro L, Christiansen S, Varela M et al (2007) Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol 83:135–144
Wikstrand CJ, McLendon RE, Friedman AH et al (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57:4130–4140
Zalutsky MR (2004) Targeted radiotherapy of brain tumours. Br J Cancer 90:1469–1473
Zalutsky MR (2005) Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med 46(Suppl 1):151S–156S
Zalutsky MR, Moseley RP, Coakham HB et al (1989) Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49:2807–2813
Zalutsky MR, Moseley RP, Benjamin JC et al (1990) Monoclonal antibody and F(ab’)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 50:4105–4110
Zalutsky MR, Reardon DA, Akabani G et al (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49:30–38
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pöpperl, G. (2012). Radioimmunotherapy of Brain Tumors. In: Baum, R. (eds) Therapeutic Nuclear Medicine. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2012_730
Download citation
DOI: https://doi.org/10.1007/174_2012_730
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-36718-5
Online ISBN: 978-3-540-36719-2
eBook Packages: MedicineMedicine (R0)